(S,E)-2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzylidene)propanehydrazide | 787504-88-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S,E)-2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzylidene)propanehydrazide
• 英文别名: 2-amino-3-hydroxy-N-[(E)-(2,3,4-trihydroxyphenyl)methylideneamino]propanamide
• CAS: 787504-88-5
• 化学式: C₁₀H₁₃N₃O₅
• 分子量: 255.23
• InChiKey: ZYTUVQILDHABLA-KGVSQERTSA-N

物化性质

• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  148
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• Small molecule binding pockets in nucleic acids
  申请人：Nymirum, Inc.

  公开号：US10522239B2

  公开（公告）日：2019-12-31

  Described herein is technology for determining the 2-D or 3-D atomic resolution structure of a polynucleotide bound to and/or interacting with another molecule, for example a small molecule. In some aspects of the technology, NMR and isotopic labeling strategies are used. The technology described herein is useful for a plurality of applications including but not limited to drug discovery and chemical biology probe discovery.

  本文描述的技术用于确定与另一种分子（例如小分子）结合和/或相互作用的多核苷酸的二维或三维原子分辨率结构。在该技术的某些方面，使用了核磁共振和同位素标记策略。本文所述技术可用于多种应用，包括但不限于药物发现和化学生物学探针发现。
• SMALL MOLECULE BINDING POCKETS IN NUCLEIC ACIDS
  申请人：Nymirum, Inc.

  公开号：US20170032078A1

  公开（公告）日：2017-02-02

  Described herein is technology for determining the 2-D or 3-D atomic resolution structure of a polynucleotide bound to and/or interacting with another molecule, for example a small molecule. In some aspects of the technology, NMR and isotopic labeling strategies are used. The technology described herein is useful for a plurality of applications including but not limited to drug discovery and chemical biology probe discovery.
• [EN] SMALL MOLECULE INHIBITORS OF ENPP1<br/>[FR] INHIBITEURS À PETITES MOLÉCULES D'ENPP1
  申请人：[en]THE REGENTS OF THE UNIVERSITY OFCALIFORNIA

  公开号：WO2022056068A1

  公开（公告）日：2022-03-17

  The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myocardial infarction and heart failure.